insiderwall
Menu
SuperinvestorInsider
Adma Biologics Inc. ADMA

Super Investor & Insider

Nessuna transazione insider negli ultimi 6 mesi.

Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.

About

ADMA Biologics Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for treating immune deficiencies and infectious diseases in the United States and internationally. Its primary products include BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) ther

SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees640
TickerADMA

Statistics

Market Cap$1.95B
Revenue (TTM)$510.2M
Net Income$146.9M
Net Margin28.8%
EPS$0.60
P/E12.24
P/S3.78
P/B4.95
EV/EBITDA203.49
ROE43.3%
Dividend Yield
Price$8.41

Data: Twelve Data · Revenue = mcap / P/S